Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
AssigneeHorizon Therapeutics USA, Inc.
InventorsTheresa Rosario-Jansen, David Erick Wright
Life of this patent
Estimating the term…
Abstract
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Claims22
A method of lowering the risk of an infusion reaction while treating chronic gout refractory to conventional therapy in a patient, the method comprising:
- a. intravenously administering to the patient a PEGylated uricase protein every 2 weeks or every 4 weeks;
- b. measuring the serum uric acid level of the patient after each said administration;
- and
- c. either continuing to administer the PEGylated uricase protein if the patient's serum uric acid is measured to be less than 6 mg/dl, or discontinuing administration of the PEGylated uricase protein if the patient's serum uric acid level is measured to be at least 6 mg/dl, thereby lowering the risk of an infusion reaction.
A method of lowering the risk of infusion reactions while treating chronic gout refractory to conventional therapy in a patient, the method comprising:
- a. intravenously administering to the patient pegloticase every 2 weeks or every 4 weeks;
- b. measuring the serum uric acid level of the patient after each said administration;
- and
- c. either continuing to administer pegloticase if the patient's serum uric acid is measured to be less than 6 mg/dl, or discontinuing administration of pegloticase if the patient's serum uric acid level is measured to be at least 6 mg/dl, thereby lowering the risk of an infusion reaction.
Dependencies are inferred from the claim text.